hyposensitization

(redirected from Allergy immunotherapy)
Also found in: Medical.

hyposensitization

[¦hī·pō‚sen·səd·ə′zā·shən]
(communications)
Mentioned in ?
References in periodicals archive ?
has received approval for the extension of the indication for Actair, an allergy immunotherapy sublingual tablet for the treatment of house dust mite (HDM) induced allergic rhinitis, to treat patients under the age of 12, the company said.
Actair is an allergy immunotherapy sublingual tablet that is used to treat house dust mite (HDM) induced allergic rhinitis.
Allergy immunotherapy, by either subcutaneous injection or sublingual tablets, is the most effective long-term treatment for dust mite allergies.
Stallergenes Greer plc is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services.
Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs.
Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Mercks house dust mite sublingual allergy immunotherapy (SLIT) tablet.
Although HDM allergic rhinitis can be treated symptomatically with oral antihistamines and nasal steroids, allergy immunotherapy has the appeal of addressing the underlying disease mechanism and potentially altering the long-term course.
ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK[R] (GRAZAX[R]) [online press release].
The closest thing to a cure is allergy immunotherapy, a means of building up tolerance to allergies by taking increasing dosages of allergic substances, similar to immunization for the flu.
SAN ANTONIO -- Once-daily use of an investigational sublingual allergy immunotherapy liquid extracted from ragweed pollen resulted in highly significant and clinically meaningful improvements in ragweed allergy symptoms in a pivotal phase III multicenter trial of more than 400 patients.
SAN ANTONIO -- GREER[R], a leading developer and provider of allergy immunotherapy products and services, announces the release of new data from its pivotal Phase III investigational clinical trial evaluating the efficacy and safety of GREER Sublingual (standardized short ragweed extract) Allergy Immunotherapy Liquid (SAIL)[TM], as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen.
Major Finding: Of surveyed offices, 53% reported performing recommended allergy immunotherapy (AIT) pre-injection health assessment, 23% reported measuring peak flow, and 33% reported routinely having patients wait the recommended 30 minutes following AIT.

Full browser ?